| dbo:abstract
|
- Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012. Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued. A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma. As of 2017, no clinical trials were in progress. (en)
- Linsitinib é uma droga experimental camndidata ao tratamento de vários tipos de câncer. É uma enzima inicidora do IGF-1R. Ela previne a proliferação celular. è de uso oral. Linsitinib está em Fase III de pesquisa para carcinoma de supra-renal e fase II para cancer pulmonar e ovariano. (pt)
|
| dbo:alternativeName
| |
| dbo:iupacName
|
- (1s,3s)-3-[8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol (en)
|
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4339 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:imagefile
| |
| dbp:imagesize
| |
| dbp:othernames
| |
| dbp:pin
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Linsitinib é uma droga experimental camndidata ao tratamento de vários tipos de câncer. É uma enzima inicidora do IGF-1R. Ela previne a proliferação celular. è de uso oral. Linsitinib está em Fase III de pesquisa para carcinoma de supra-renal e fase II para cancer pulmonar e ovariano. (pt)
- Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted orphan drug designation for adrenocortical carcinoma in March 2012. (en)
|
| rdfs:label
|
- Linsitinib (en)
- Linsitinib (pt)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
